Moderna, Inc. MRNA
Set alert
220.83 USD -0.89 -0.40%
At close · Nov 2
220.25 -0.58 -0.26%
After hours · Nov 2, 7:41 PM ET
217.66 Day range 230.52
22.28 52-week range 254.48
- YTD
- +648.83%
- 1 year
- +713.07%
- Open
- 224.16
- Prev close
- 221.72
- Mkt cap
- 88.16B
- Vol
- 8.44M
- Avg vol
- 21.30M
- EPS
- -7.98
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 217.66
- High
- 230.52
- Forward P/E
- -48.16
- Beta
- 1.17
- Short ratio
- 1.86
- Inst. own
- 80.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 6, 2026
- 50-d avg
- 182.49
- 200-d avg
- 86.58
- 1y target
- 138.37
6M chart
Events in this range
- Jul 31, 2026Earnings: -1.97; estimate -2.03; surprise 2.96%
- Sep 30, 2026Downgrade: Citigroup · Neutral → Sell
- Oct 7, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
- Oct 15, 2026Rating: Goldman Sachs · Neutral → Neutral
- Oct 21, 2026Rating: TD Cowen · Hold → Hold
- Oct 26, 2026Rating: Piper Sandler · Overweight → Overweight
- Oct 27, 2026Downgrade: William Blair · Outperform → Market Perform
Signals (38)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 22, 2026 | 1 week ago |
| RSI: Overbought | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 3 weeks ago |
| RSI: Overbought | Oct 9, 2026 | 3 weeks ago |
| RSI: Overbought | Oct 5, 2026 | 4 weeks ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| RSI: Overbought | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| RSI: Overbought | Aug 21, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 29, 2026 | 3 months ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| SMA: Bearish | Jul 23, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| RSI: Overbought | Jun 26, 2026 | 4 months ago |
| RSI: Overbought | Jun 17, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 5 months ago |
| SMA: Bearish | Jun 5, 2026 | 5 months ago |
| SMA: Bullish | Jun 4, 2026 | 5 months ago |
| SMA: Bullish | Jun 3, 2026 | 5 months ago |
| MACD: Buy Signal | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 19, 2026 | 5 months ago |
| MACD: Sell Signal | May 19, 2026 | 5 months ago |
| SMA: Bearish | May 13, 2026 | 5 months ago |
| SMA: Bullish | May 8, 2026 | 5 months ago |
| MACD: Buy Signal | May 8, 2026 | 5 months ago |
Key statistics
- Market cap
- 88.16B
- Enterprise value
- 84.67B
- Trailing P/E
- 0.00
- Forward P/E
- -48.16
- PEG ratio
- 0.00
- Price / sales
- 39.57
- Price / book
- 13.03
- EPS (TTM)
- -7.98
- Beta
- 1.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -141.43%
- Revenue (TTM)
- 2.23B
- Revenue growth
- 2.10%
- Free cash flow
- 299.25M
- Total cash
- 5.14B
- Total debt
- 1.29B
- Return on equity
- -39.00%
- Shares outstanding
- 399.24M
- Short % of float
- 9.98%
- 50-day average
- 182.49
- 200-day average
- 86.58
Analyst view
Consensus: hold
Hold
Price target (mean) 138.37 -37.3% downside
Now 220.83
- Target (low)
- 45.00
- Target (mean)
- 138.37
- Target (high)
- 251.00
Ratings (0m) 23 4 buy · 15 hold · 4 sell
- Strong buy1
- Buy3
- Hold15
- Sell2
- Strong sell2
Next earnings
Nov 6, 2026
Expected Nov 6, 2026. Consensus EPS estimate -1.35.
Financials — quick view
MRNA Revenue — quarterly 145.00M
MRNA Net income — quarterly -782.00M
MRNA EPS — quarterly -1.97
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2026 | Sep 30, 2026 | -1.10 | — | — | — |
| Jul 31, 2026 | Jun 30, 2026 | -2.03 | -1.97 | +0.06 | +2.96% |
| May 1, 2026 | Mar 31, 2026 | -4.45 | -3.40 | +1.05 | +23.60% |
| Feb 13, 2026 | Dec 31, 2025 | -2.54 | -2.11 | +0.43 | +16.93% |
| Nov 6, 2025 | Sep 30, 2025 | -1.87 | -0.51 | +1.36 | +72.73% |
| Aug 1, 2025 | Jun 30, 2025 | -2.99 | -2.13 | +0.86 | +28.76% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | William Blair | down | Outperform | Market Perform |
| Oct 26, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Oct 21, 2026 | TD Cowen | main | Hold | Hold |
| Oct 15, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Oct 7, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Sep 30, 2026 | Citigroup | down | Neutral | Sell |
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- modernatx.com
News
- Buy Moderna Stock Before Q3 Earnings? Here's What to Know
- Stock Split Watch: Is Moderna Next?
- Tempus AI Earnings Ahead: Is TEM Set Up To Pop or Drop?
- Moderna, Merck eye FDA approval for promising cancer vaccine
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week
- Earnings Volatility Watch: 10 Stocks Are Set to Swing More Than 10% This Week
- Merck One of Top Large-Cap Biopharma Picks-Analyst
- Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
- Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
- GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
Your note
Sign in to keep a note on MRNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AFEYAN NOUBAR BOGHOS | Director | Sale | May 20, 2026 | 0 |
| BANCEL STEPHANE J | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 5, 2026 | 22,215,800 |
| HOGE STEPHEN | President | Conversion of Exercise of derivative security | Sep 14, 2026 | 1,718,080 |
| HORNING SANDRA | Director | Conversion of Exercise of derivative security | Apr 29, 2026 | 18,585 |
| HUSSAIN SHAH ABBAS | Director | Sale | Apr 30, 2026 | 12,066 |
| KLINGER SHANNON THYME | Officer | Conversion of Exercise of derivative security | Sep 3, 2026 | 81,340 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.99% | 51,859,891 | 11.45B | Jun 29, 2026 |
| Blackrock Inc. | 7.66% | 30,599,409 | 6.76B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 5.81% | 23,208,792 | 5.13B | Jun 29, 2026 |
| Capital World Investors | 5.58% | 22,276,996 | 4.92B | Jun 29, 2026 |
| BAILLIE GIFFORD & CO | 4.56% | 18,206,778 | 4.02B | Jun 29, 2026 |
| State Street Corporation | 3.94% | 15,726,193 | 3.47B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Growth Fund of America | 3.75% | 14,983,229 | 3.31B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.84% | 11,331,692 | 2.50B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.29% | 9,154,510 | 2.02B | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.06% | 8,239,175 | 1.82B | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.05% | 8,190,072 | 1.81B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.30% | 5,187,970 | 1.15B | Jun 29, 2026 |